N/A N=19 Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes
Type1diabetes, Low Carbohydrate Diet
Primary: Percent Time in the Optimal Glucose Range — 71.20; 62.51 percentage of time — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Assessing an Animal-Assisted Treatment Program for Adults With Aphasia: The Persons With Aphasia Training Dogs Program
Aphasia
Primary: Assessment of Living With Aphasia (ALA, Kagan et al., 2010) — 2.67; 2.33; 2.68; 2.43 units on a scale
Phase 3 N=198 Phase 2/3 Study of ALK-001 in Geographic Atrophy
Geographic Atrophy · Age Related Macular Degeneration · AMD
Primary: Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF) — 1.62; 1.87 mm2/year
N/A N=38 rTMS to Enhance Cognitive Performance and Promote Resilience
Cognition · Stress Reaction
Primary: Mean Score of Neurocognitive Performance (Fluid Cognition) — 63.500; 50.250; 59.750; 57.250 score on a scale
Phase 2 N=216 A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: Median Time to Solid Food Tolerance, With gMCP Modeling Analysis for Dose-response Relationship — 67.0; 64.0; 78.0; 66.0 Hours — p=0.3184
Phase 3 N=2,859 TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
Heart Failure
Primary: All-cause Mortality, as Measured by Follow-up Phone Call or NDI — 373; 374 Participants — p=0.765
N/A N=900 Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention
Behavior, Health · Child Obesity
Primary: Child Weight for Length Trajectory — 8.0; 8.0; 9.3; 9.4 kg/m — p=<0.001
N/A N=1,400 Assessment of a Fruit and Vegetable Prescription Program for Children
Exposure to Fruit and Vegetable Prescription Program
Primary: Change From Baseline Child-reported Mean Daily Intake of Fruits and Vegetables at 6 and 12 Months Among Youth Participants Newly Introduced to the FVPP — 0.21; 0.17…
N/A N=14 VR Cognitive Rehabiliation for Pediatric TBI
TBI (Traumatic Brain Injury)
Primary: VR-based EF Assessment Task — 1.41; 1.53; 1.71; 1.82 Z-Score
Early Phase 1 N=64 Muscadine Grape Extract to Improve Fatigue
Fatigue
Primary: Patient Reported Outcomes Measurement System (PROMIS) Fatigue 7a Questionnaire — -6.6; -5.4 score on a scale
N/A N=18 Imaging Biomarkers of Lymphatic Dysfunction
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Phase 4 N=65 QL Block With Exparel in Colectomy
Laparotomy · Colectomy
Primary: Cumulative Opioid Consumption Over 48 Hours — 33; 61 morphine milligram equivalents
N/A N=3,820 A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study
Metastatic Solid Tumors
Primary: Count of Participants With NRTK Fusions Among Participants Analyzed by NGS (Next-generation Sequencing). — 11 Participants
Phase 3 N=119 Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Psoriatic Arthritis
Primary: Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 — 32; 17 Participants — p=0.002
Phase 1 N=37 Epigenetic Reprogramming in Relapse/Refractory AML
Acute Myelogenous Leukemia
Primary: The Dose of Decitabine That Can be Safely Given With Vorinostat, Fludarabine, High Dose Cytarabine and G-CSF (FLAG) — 3; 20; 12; 0 Participants